Home
How It Works
Solutions
For Academic Experts
Resources
Blog
Case Studies
Request Demo
Sign Up
Login

Work with thought leaders and academic experts in hepatology

Companies can greatly benefit from collaborating with an academic researcher specializing in hepatology. Here are a few reasons why:

Experts on NotedSource with backgrounds in hepatology include Luke Connelly, Marina Baretti, Matthew Laye, Ph.D., Mehrdad Sheikhvatan, and John Joe.

Luke Connelly

Professor of Health Economics, The University of Queensland, CBEH
Most Relevant Research Interests
Hepatology
Other Research Interests (52)
Health economics
insurance
Public Health, Environmental and Occupational Health
Safety, Risk, Reliability and Quality
Human Factors and Ergonomics
And 47 more
About
Luke Connelly is Professor of Health Economics at the Centre for the Business and Economics of Health. He also holds a Professorial appointment (part-time) at The University of Bologna, to which he was appointed in 2017 via the Italian “Direct Call” ([link](https://www.unibo.it/sitoweb/luke.connelly/en)) process. In 2019 he was appointed as Honorary Professor at The University of Sydney. His main interests are in health economics and insurance economics and the effects of institutions (including legal constructs) on incentives and behaviour. He has also worked in other fields of applied microeconomics, including education economics and transport economics. His publications include papers in *Review of Income and Wealth*, *Health Economics*, *Journal of Health Economics*, *Journal of Risk and Insurance*, *Geneva Papers on Risk and Insurance*, *Accident Analysis and Prevention*, *Journal of Law and Medicine*, *Journal of Clinical Epidemiology*, *European Journal of Health Economics*, *International Journal of Health Economics and Finance*, *Social Science and Medicine*, *Economic Papers*, *Economic Analysis and Policy*, *Journal of Transport Economics and Policy*, *Labour Economics*, *Economics and Human Biology* as well as in a range of clinical journals, including *Lancet*. Luke has served on a number of public committees including the Medical Services Advisory Committee (MSAC), which advises the Australian Minister for Health on the safety, efficacy, effectiveness, and cost-effectiveness of new and extant listings on Australia's Medicare Benefits Schedule. He has extensive service on other public committees and taskforces as well as extensive teaching and consulting engagements with industry. Over his career he has been a chief investigator on research grants and contracts totalling more than $67m. He is a member of the Editorial Boards of European Journal of Health Economics and the International Journal on Environmental Research and Public Health. He is a member of the International Health Economics Association's Arrow Awards Committee, which awards an annual prize in honour of Nobel Laureate Kenneth Arrow for the best paper in the field. He is currently Guest Editor (with Christophe Courbage) on a Special Issue of the Geneva Papers on Risk and Insurance on Insurance and Emerging Health Risks. His current research interests include health service innovations to improve the health of people with chronic kidney disease(CKD). Ongoing interests include the economics of disability and insurance, compensable injury compensation schemes, and the determinants of health. Luke enjoys and has considerable experience teaching economics and health economics at both the graduate and undergraduate levels. In 2014 he was awarded the School of Economics Distinguished Teaching Award for his teaching on UQ's Master of Health Economics Program. In July 2016 and July 2019 he also taught summer schools in Health Economics and the Economics of Insurance at The University of Lucerne, Switzerland. Over the past 10 years he has been a chief investigator on grants totalling more than $70m.
Most Relevant Publications (1+)

105 total publications

Economic evaluation of fecal microbiota transplantation for the treatment of recurrentClostridium difficileinfection in Australia

Journal of Gastroenterology and Hepatology / Nov 29, 2016

Merlo, G., Graves, N., Brain, D., & Connelly, L. B. (2016). Economic evaluation of fecal microbiota transplantation for the treatment of recurrentClostridium difficileinfection in Australia. Journal of Gastroenterology and Hepatology, 31(12), 1927–1932. Portico. https://doi.org/10.1111/jgh.13402

Marina Baretti

Baltimore, Maryland, United States of America
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Most Relevant Research Interests
Hepatology
Other Research Interests (19)
Oncology
Pharmacology (medical)
Pharmacology
Hematology
Gastroenterology
And 14 more
About
Throughout my training, I have been focused toward my ultimate goal of becoming a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions. My clinical research is centered on the development of novel agents in GI cancers, with particular interest in combinatorial approaches of epigenetic therapies and immunotherapies combinations. I ran the first phase II study of combination epigenetic therapy and immunotherapy in advanced pancreatic adenocarcinoma and cholangiocarcinoma, working with a collaborative team that incorporates leading experts in cancer immunology, epigenetics and drug development. I was awarded the 2018 ASCO Conquer Cancer Foundation Young Investigator Award for this project.  Together with Dr. Yarchoan, we are running a clinical trial of a novel neoantigen-specific vaccine in combination with immune checkpoint inhibitors for advanced fibrolamellar carcinoma (FLC) (NCT04248569). My laboratory focus has been on developing and validating a preclinical mouse model of FLC to investigate mechanisms underlying FLC pathogenesis, and will become a critical tool for investigating novel therapeutic strategies in FLC.
Most Relevant Publications (4+)

57 total publications

Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer

Digestive and Liver Disease / Oct 01, 2015

Sefrioui, D., Sarafan-Vasseur, N., Beaussire, L., Baretti, M., Gangloff, A., Blanchard, F., Clatot, F., Sabourin, J.-C., Sesboüé, R., Frebourg, T., Michel, P., & Di Fiore, F. (2015). Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Digestive and Liver Disease, 47(10), 884–890. https://doi.org/10.1016/j.dld.2015.05.023

Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors

Pancreas / May 01, 2021

Baretti, M., Zhu, Q., Zahurak, M., Bhaijee, F., Xu, H., Engle, E. L., Kotte, A., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2021). Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas, 50(5), 719–726. https://doi.org/10.1097/mpa.0000000000001831

Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma

Hepatology / Aug 21, 2021

Solipuram, V., Baretti, M., Kim, A. Y., Chen, L. X., Fahrner, J. A., Gunay‐Aygun, M., Peng, X. P., Hardenbergh, D., Ferguson, A., Griffith, P., Wang, Y., Brancati, M., Gopalakrishna, H., Kato, T., Shubert, C., Laheru, D., & Yarchoan, M. (2021). Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma. Hepatology, 74(5), 2899–2901. https://doi.org/10.1002/hep.31998

The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma

Pancreas / Apr 01, 2019

Baretti, M., Pulluri, B., Tsai, H.-L., Blackford, A. L., Wolfgang, C. L., Laheru, D., Zheng, L., Herman, J., Le, D. T., Narang, A. K., & de Jesus-Acosta, A. (2019). The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas, 48(4), 585–589. https://doi.org/10.1097/mpa.0000000000001262

Matthew Laye, Ph.D.

Medical Physiology Teacher, Data Scientist, Endurance Coach, Wearable Technology Consultant, Writer About Research
Most Relevant Research Interests
Hepatology
Hepatology
Other Research Interests (25)
Physiology
Physiology (medical)
Gastroenterology
Multidisciplinary
Public Health, Environmental and Occupational Health
And 20 more
Most Relevant Publications (5+)

55 total publications

Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model

Journal of Hepatology / May 01, 2010

Rector, R. S., Thyfault, J. P., Uptergrove, G. M., Morris, E. M., Naples, S. P., Borengasser, S. J., Mikus, C. R., Laye, M. J., Laughlin, M. H., Booth, F. W., & Ibdah, J. A. (2010). Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. Journal of Hepatology, 52(5), 727–736. https://doi.org/10.1016/j.jhep.2009.11.030

Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats

American Journal of Physiology-Gastrointestinal and Liver Physiology / Mar 01, 2008

Rector, R. S., Thyfault, J. P., Morris, R. T., Laye, M. J., Borengasser, S. J., Booth, F. W., & Ibdah, J. A. (2008). Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. American Journal of Physiology-Gastrointestinal and Liver Physiology, 294(3), G619–G626. https://doi.org/10.1152/ajpgi.00428.2007

T1620 Loss of Mitochondrial Content and Function Contribute to the Natural History of Nonalcoholic Fatty Liver Disease in a Hyperphagic Obese Rodent Model

Gastroenterology / May 01, 2009

Rector, S., Thyfault, J. P., Uptergrove, G. M., Morris, E. M., Naples, S. P., Borengasser, S. J., Mikus, C. R., Laye, M. J., Laughlin, M. H., Booth, F. W., & Ibdah, J. A. (2009). T1620 Loss of Mitochondrial Content and Function Contribute to the Natural History of Nonalcoholic Fatty Liver Disease in a Hyperphagic Obese Rodent Model. Gastroenterology, 136(5), A-850. https://doi.org/10.1016/s0016-5085(09)63920-2

S1894 Physical Activity and Short-Term Inactivity Modulate Hepatic Fatty Acid Oxidation and Lipogenesis Proteins in Otsuka Long-Evans Tokushima Fatty (Oletf) Rats

Gastroenterology / Apr 01, 2008

Rector, S., Thyfault, J. P., Laye, M. J., Morris, R. T., Borengasser, S. J., Uptergrove, G. M., Booth, F. W., & Ibdah, J. A. (2008). S1894 Physical Activity and Short-Term Inactivity Modulate Hepatic Fatty Acid Oxidation and Lipogenesis Proteins in Otsuka Long-Evans Tokushima Fatty (Oletf) Rats. Gastroenterology, 134(4), A-778-A-779. https://doi.org/10.1016/s0016-5085(08)63636-7

S1894 Physical Activity and Short-Term Inactivity Modulate Hepatic Fatty Acid Oxidation and Lipogenesis Proteins in Otsuka Long-Evans Tokushima Fatty (Oletf) Rats

Gastroenterology / Apr 01, 2008

Rector, S., Thyfault, J. P., Laye, M. J., Morris, R. T., Borengasser, S. J., Uptergrove, G. M., Booth, F. W., & Ibdah, J. A. (2008). S1894 Physical Activity and Short-Term Inactivity Modulate Hepatic Fatty Acid Oxidation and Lipogenesis Proteins in Otsuka Long-Evans Tokushima Fatty (Oletf) Rats. Gastroenterology, 134(4), A-778-A-779. https://doi.org/10.1016/s0016-5085(08)63636-7

Mehrdad Sheikhvatan

Iran University of Medical Sciences
Most Relevant Research Interests
Hepatology
Other Research Interests (58)
Molecular Cardiogenetic
Obstetrics and Gynecology
Neurology (clinical)
Otorhinolaryngology
Gastroenterology
And 53 more
Most Relevant Publications (3+)

90 total publications

Hepatobiliary & Pancreatic Diseases International (HBPD INT)

Hepatobiliary & Pancreatic Diseases International / Aug 01, 2014

Hepatobiliary & Pancreatic Diseases International (HBPD INT). (2014). Hepatobiliary & Pancreatic Diseases International, 13(4), A2. https://doi.org/10.1016/s1499-3872(14)60287-3

The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation

Digestive and Liver Disease / Sep 01, 2009

Zojaji, H., Talaie, R., Mirsattari, D., Haghazali, M., Molaei, M., Mohsenian, N., Derakhshan, F., & Zali, M. R. (2009). The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. Digestive and Liver Disease, 41(9), 644–647. https://doi.org/10.1016/j.dld.2008.09.008

The Efficacy and Tolerability of Mebeverine in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials

Gastroenterology / Apr 01, 2017

Mokhtare, M., Boghratian, A., Agah, S., & Sheikhvatan, M. (2017). The Efficacy and Tolerability of Mebeverine in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials. Gastroenterology, 152(5), S719–S720. https://doi.org/10.1016/s0016-5085(17)32503-9

John Joe

Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
Most Relevant Research Interests
Hepatology
Other Research Interests (73)
microbiology
systems biology
genetics
quantum biology
Genetics
And 68 more
Most Relevant Publications (2+)

95 total publications

Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients

Alimentary Pharmacology & Therapeutics / Mar 31, 2007

HAMPSON, S. J., PARKER, M. C., SAVERYMUTTU, S. H., JOSEPH, A. E., MCFADDEN, J.-J. P., & HERMON-TAYLOR, J. (2007). Quadruple antimycobacterial chemotherapy in Crohn’s disease: results at 9 months of a pilot study in 20 patients. Alimentary Pharmacology & Therapeutics, 3(4), 343–352. https://doi.org/10.1111/j.1365-2036.1989.tb00221.x

Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis

Journal of Hepatology / Mar 01, 1998

O’Donohue, J., Fidler, H., Garcia-Barcelo, M., Nouri-Aria, K., Williams, R., & McFadden, J. (1998). Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. Journal of Hepatology, 28(3), 433–438. https://doi.org/10.1016/s0168-8278(98)80317-6

Example hepatology projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on hepatology?

Drug Development and Clinical Trials

An academic researcher in hepatology can contribute to the development of new drugs and therapies for liver diseases. They can design and conduct clinical trials, analyze data, and provide valuable insights into the efficacy and safety of potential treatments.

Diagnostic Tools and Biomarkers

Collaborating with a hepatology expert can lead to the development of advanced diagnostic tools and biomarkers for liver diseases. These tools can improve early detection, prognosis, and personalized treatment strategies, ultimately benefiting patients and healthcare providers.

Genomic and Proteomic Research

Hepatology researchers can contribute to genomic and proteomic studies focused on understanding the molecular mechanisms underlying liver diseases. This knowledge can help identify novel therapeutic targets and biomarkers, paving the way for precision medicine approaches.

Liver Disease Epidemiology

Academic researchers in hepatology can collaborate with companies to conduct epidemiological studies on liver diseases. This research can provide valuable insights into disease prevalence, risk factors, and trends, enabling companies to develop targeted prevention and intervention strategies.

Healthcare Policy and Guidelines

Companies can benefit from the expertise of hepatology researchers in shaping healthcare policies and guidelines related to liver diseases. Their insights can contribute to the development of evidence-based practices, improved patient care, and better allocation of healthcare resources.